Edward G. Lufkin
United States Department of the Army
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Edward G. Lufkin.
The New England Journal of Medicine | 1975
Clifford W. Zwillich; David J. Pierson; Fred D. Hofeldt; Edward G. Lufkin; John V. Weil
Alveolar hypoventilation is known to occur in myxedema. To clarify the role of hypoxic ventilatory drive and hypercapnic ventilatory drive in thyroid hormone insufficiency states, 10 patients with myxedema and seven with hypothyroidism (thyroid ablation) were studied before and after thyroid replacement. An index developed for hypoxic ventilatory drive was markedly reduced in myxedema: 17 plus or minus 4.7 (S.E.M.) (normal, 126 plus or minus 8.7) (P smaller than 0.01) and increased to 78 plus or minus 12.6 (p = 0.02) with thyroid hormone replacement. In the hypothyroid group this index was also depressed as compared to normal at 67 plus or minus 20 (p smaller than 0.01) and increased to 114 plus or minus 19 (p smaller than 0.02) with replacement. An index for hypercapnic ventilatory drive was depressed in myxedema, 0.69 plus or minus 0.01), but was not significantly depressed in hypothyroidism. With thyroid hormone replacement this index did not significantly increase in either group. We conclude that both myxedema and hypothyroid states produce depression of hypoxic ventilatory drive that is responsive to replacement therapy. This alteration in ventilatory control may contribute to the hypoventilation seen in myxedema.
Diabetes | 1974
Fred D. Hofeldt; Edward G. Lufkin; Louis Hagler; Marshall B. Block; Stephen E Dippe; John W Davis; Seymour R. Levin; Peter H. Forsham; Robert H. Herman
Seventy patients with reactive hypoglycemia strictly defined by criteria which interpret the low blood glucose value in relationship to clinical and physiologic parameters, were studied to determine if abnormalities in insulin secretion could be demonstrated. These patients were separated into four groups: alimentary (N = 5), diabetic (N = 16), hormonal (N = 5), and idiopathic (N = 44). The findings in these patients were compared to normal control subjects and to weight- and disease-matched patient controls. All of the patients with hormonal and most patients with idiopathic reactive hypoglycemia (thirty-two of forty-four) demonstrated delayed insulin secretion regardless of the control group used for comparison. Diabetic reactive hypoglycemic patients exhibited delayed insulin secretion when compared to normal controls but not when compared to weight-matched diabetic controls. Excessive insulin secretion was consistently found only in the patients with the alimentary variety of reactive hypoglycemia. Using weight- and diseasematched control groups, no abnormalities in insulin secretion could be found to account for the hypoglycemia in the diabetic reactive hypoglycemic patients and some idiopathic reactive hypoglycemic (nine of forty-four) patients. These results help to explain the inconsistent findings of previous investigators and suggest that reactive hypoglycemia is a syndrome having multiple etiologies.
Metabolism-clinical and Experimental | 1975
Edward G. Lufkin; O. David Taunton; Fred B. Stifel; Norton S. Rosensweig; Louis Hagler; Richard S. Teplick; Robert H. Herman
The activities of jejunal carbohydrate-metabolizing enzymes show adaptive drugs, and sex hormones. To learn whether insulin, tolbutamide, and glucagon had effects on these enzymes, we performed serial peroral jejunal biopsies in normal young men and in obese patients, before and after treatment with these agents. Jejunal mucosa was assayed for glycolytic enzyme activities, pyruvate kinase (PK), hexokinase (HK), and fructose-1,6-diphosphate aldolase (FDPA), and the nonglycolytic enzyme activity, fructose diphosphatase (FDPase). Insulin significantly increased the activity of jejunal PK (+48% change from control) and HK (+6%), decreased the activity of FDPase (-36%),and had no effect on FDPA. Glucagon had opposite effects; the activity of PK was decreased (-33%) and FDPase was increased (+50%). Tolbutamide significantly increased the activities of PK (+47%), HK (+14%), and FDPA (+7%), and decreased the activities of FDPase (-36%). The results of tolbutamide on glycolytic enzyme activities were independent of endogenous insulin. The data support the concept that jejunal carbohydrate-metabolizing enzymes in man respond to hormones and drugs similar to responses observed in rat liver. This is important because it now gives us a means of studying the actions of these hormones directly in human tissue.
Biochimica et Biophysica Acta | 1976
Fred B. Stifel; Harry L. Greene; Edward G. Lufkin; Margaret R. Wrensch; Louis Hagler; Robert H. Herman
1. Oral administration of ethanol (3 ml) of 95% in 12 ml total volume over a two day period) significantly decrease plasma glucose and insulin levels and the activities of two key gluconeogenic enzymes, pyruvate carboxylase (pyruvate: CO2 ligase (ADP), EC 6.4.1.1) and fructose diphosphatase, (D-Fru-1,6-P2 1-phosphohydrolase, EC 3.1.3.11), and one glycolytic enzyme, fructose-1,6-P2 aldolase (Fru-1,6-P2 D-glyceraldehyde-3-P lyase, EC 4.1.2.13). In each instance, the administration of 2400 mug daily of oral folate in conjuction with the ethanol prevented these alterations in carbohydrate metabolism. 2. Intravenous injection of ethanol produced a rapid decrease (within 10--15 min) in the activities of hepatic phosphofructokinase, (ATP:D-fructose-6-phosphate 6-phosphotransferase, EC 2.7.1.11), pyruvate kinase, (ATP:pyruvate phosphotransferase, EC 2.7.1.40), fructose diphosphatase and fructose-1,6-P2 aldolase. 3. Intravenous ethanol significantly increased hepatic cyclic AMP concentration approximately 60% within 10 min, while oral ethanol did not alter hepatic cyclic AMP concentrations. 4. These data confirm the known antagonism ethanol and folate and suggest that oral folate might offer a protective effect against hypoglycemia in rats receiving ethanol.
The American Journal of the Medical Sciences | 1972
Edward G. Lufkin; Fred H. Katz; Robert H. Herman
We have studied a 41-year-old man who had asymptomatic hypertension, hypokalemia, very low plasma renin, elevated plasma aldosterone, and elevated aldosterone secretion rate. These abnormalities persisted despite marked restriction of sodium intake, upright position, furosemide, DOCA injection, and angiotension infusion. These abnormalities are typical of primary aldosteronism due to adrenocortical adenoma. At surgery, however, no discrete adenoma was found. The adrenals were of normal size, and histologically revealed diffuse bilateral hyperplasia of the zona glomerulosa. Hypertension recurred postoperatively, but plasma renin and aldosterone returned to normal. This patient demonstrates that adreno-cortical adenoma and hyperplasia are presently indistinguishable causes of primary aldosteronism, and have a different prognosis.
The Journal of Clinical Endocrinology and Metabolism | 1980
Edward G. Lufkin; David M. Wilson; Lynwood H. Smith; Nancy J. Bill; Hector F. DeLuca; Thomas P. Dousa; Franklyn G. Knox
Archives of Dermatology | 1974
Kenneth H. Neldner; Louis Hagler; William R. Wise; Fred B. Stifel; Edward G. Lufkin; Robert H. Herman
JAMA Internal Medicine | 1985
Richard A. DeRemee; Edward G. Lufkin; Michael S. Rohrbach
The Journal of Clinical Endocrinology and Metabolism | 1972
Edward G. Lufkin; Fred B. Stifel; Robert H. Herman; Norton S. Rosensweig
Fertility and Sterility | 1981
Carolyn B. Coulam; Edward G. Lufkin